Scinai Immunotherapeutics (SCNI) AI Stock Analysis

Compare

305 Followers

SCNI Dividends

Top Page

Scinai Immunotherapeutics

(NASDAQ:SCNI)

52Neutral

Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.

Scinai Immunotherapeutics (SCNI) vs. S&P 500 (SPY)

Market Cap

$1.83M

Dividend YieldN/A

Average Volume (3M)16.95K

Price to Earnings (P/E)7.9

Beta (1Y)0.69

Revenue GrowthN/A

EPS GrowthN/A

CountryUS

Employees31

SectorHealthcare

Sector Strength64

IndustryBiotechnology

Share Statistics

EPS (TTM)0.30

Shares Outstanding933,679

10 Day Avg. Volume27,706

30 Day Avg. Volume16,949

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Scinai Immunotherapeutics Business Overview & Revenue Model

Company DescriptionScinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

How the Company Makes MoneyScinai Immunotherapeutics generates revenue primarily through the development and commercialization of its immunotherapeutic products. The company earns money by progressing its drug candidates through clinical trials, obtaining regulatory approvals, and subsequently launching these products in the market. Revenue streams include product sales, licensing agreements, and strategic partnerships with other pharmaceutical or biotechnology companies. These partnerships often involve milestone payments and royalties related to the development and commercialization of SCNI's proprietary technologies. Additionally, the company may receive funding through grants and collaborations aimed at advancing its research and development efforts.

Scinai Immunotherapeutics Financial Statement Overview

Summary

Scinai Immunotherapeutics shows some signs of financial recovery with positive net income in the TTM period. However, it faces significant challenges, including negative cash flows, high debt levels, and negative margins, which could impact its sustainability and growth prospects. Continued focus on revenue generation and cost management will be crucial for future stability.

Income Statement

Negative

The company has shown some improvement in net income, transitioning from negative to positive figures in the TTM period. However, the gross profit margin is negative, indicating that the cost of goods sold is higher than the revenue. Additionally, the EBIT and EBITDA margins are inconsistent, with a significantly negative EBITDA margin in TTM, pointing to high operational costs. The revenue growth rate is not applicable due to zero revenue in previous periods.

Balance Sheet

Negative

The balance sheet shows a relatively strong equity position in the TTM period with positive stockholders' equity compared to previous negative figures. However, the debt-to-equity ratio is high due to significant total debt, indicating potential financial risk. The equity ratio has improved but remains at risk given the industry context.

Cash Flow

Neutral

The cash flow statement indicates a challenging situation with negative operating cash flow and free cash flow in the TTM period, though there is an improvement compared to previous periods. Free cash flow to net income ratio shows a concerning trend as free cash flow remains negative. The company is not generating sufficient cash to cover its operational activities.

TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
452.00K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-413.00K	0.00	0.00	0.00	0.00	0.00
	EBIT
7.37M	-9.71M	-11.06M	-10.87M	2.28M	-22.69M
	EBITDA
-6.96M	-9.19M	-10.50M	-10.39M	2.75M	-22.21M
	Net Income Common Stockholders
3.64M	-6.50M	-5.80M	-8.21M	-1.39M	-31.62M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.17M	4.87M	14.07M	17.37M	2.93M	20.98M
	Total Assets
6.82M	17.47M	27.07M	32.04M	17.71M	33.52M
	Total Debt
0.00	20.56M	21.54M	28.98M	20.90M	38.02M
	Net Debt
-4.59M	15.69M	7.47M	11.61M	17.97M	17.03M
	Total Liabilities
488.25K	22.04M	28.83M	31.05M	22.25M	52.36M
	Stockholders Equity
6.34M	-4.57M	-1.76M	982.00K	-4.54M	-18.84M
Cash Flow		Free Cash Flow
-6.73M	-10.02M	-8.10M	-7.57M	-24.48M	-24.47M
	Operating Cash Flow
-6.48M	-9.38M	-7.26M	-7.43M	-22.57M	-22.31M
	Investing Cash Flow
-246.00K	-637.00K	-836.00K	-139.00K	-1.85M	-2.08M
	Financing Cash Flow
1.44M	1.09M	6.78M	21.43M	4.27M	24.68M

Scinai Immunotherapeutics Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price2.42

Price Trends

50DMA

3.00

Negative

100DMA

3.23

Negative

200DMA

3.47

Negative

Market Momentum

MACD

-0.29

Negative

RSI

45.51

Neutral

STOCH

30.36

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Neutral. The current price of 2.42 is below the 20-day moving average (MA) of 2.43, below the 50-day MA of 3.00, and below the 200-day MA of 3.47, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 45.51 is Neutral, neither overbought nor oversold. The STOCH value of 30.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SCNI.

Scinai Immunotherapeutics Risk Analysis

Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Scinai Immunotherapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCNI	52 Neutral	$1.83M	7.93	99.42%	―	―	―
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
ELAB	39 Underperform	$1.97M	―	-130.35%	―	―	―
ZVSA	29 Underperform	$2.41M	―	-96.10%	―	―	99.39%
PTIX	27 Underperform	$1.70M	―	-236.06%	―	―	-40.51%

* Healthcare Sector Average

Performance Comparison

SCNI

Scinai Immunotherapeutics

2.42

-2.08

-46.22%

TNFA

TNF Pharmaceuticals

0.19

-2.62

-93.24%

ENTO

Entero Therapeutics

0.38

-2.35

-86.08%

PTIX

Protagenic Therapeutics

0.21

-1.36

-86.62%

ZVSA

ZyVersa Therapeutics

0.72

-5.36

-88.16%

ELAB

ELEVAI Labs Inc.

2.22

-941.38

-99.76%

Scinai Immunotherapeutics Earnings Call Summary

Earnings Call Date: Nov 22, 2024 | % Change Since: -19.87% | Next Earnings Date: May 29, 2025

Earnings Call Sentiment Neutral

The earnings call presented a mix of positive and negative aspects. While there were notable achievements such as the reduction in net loss, positive regulatory feedback, and growth in the CDMO business, there were also challenges like a significant decrease in cash position and negative shareholder equity. The sentiment is balanced with both opportunities and financial restructuring challenges.

Highlights

Reduction in Operating Expenses

R&D expenses decreased to $2.79 million compared to $3.45 million the previous year, and marketing and G&A expenses were reduced to $1 million from $2.3 million the previous year.

Net Loss Reduction

Net loss for the first 6 months of 2024 was reduced to $4.48 million compared to $7.28 million in the first 6 months of 2023.

Positive Regulatory Feedback

Received positive regulatory feedback from the Paul Erlich Institute for their drug development program towards Phase I/IIa clinical trial of their anti-IL-17 AF nanoAb in plaque psoriasis.

CDMO Business Growth

CDMO unit generated work orders valued at $600,000 from 5 clients since January 2024 with a 2024 guidance of $1.25 million.

Private Equity Commitment

Received a $2 million equity commitment from Daniel Stone through RK Stone Miami LLC, with the commitment valid until December 31, 2024.

Lowlights

Cash Position Decrease

Cash available as of June 30, 2024, was $3.21 million, down from $7.63 million at the end of June 30, 2023.

Negative Shareholder Equity

Shareholder equity was negative $7.28 million compared to negative $4.57 million as of June 30, 2023.

EIB Loan Restructuring Required

The EIB loan restructuring deal was necessary to convert a large debt into equity, highlighting financial restructuring needs.

Company Guidance

In the Q2 2024 earnings call for Scinai Immunotherapeutics, CEO Amir Reichman provided detailed guidance on the company's strategic objectives and financial outlook. Scinai aims to fast-track IL-17 development to toxicology studies and increase CDMO business unit sales to $1.25 million. The company plans to reduce R&D risks by partnering with other pharma companies while maintaining careful spending to control its burn rate. Financially, Scinai reported a net loss of $4.48 million for the first half of 2024, a decrease from $7.28 million in the same period in 2023, attributed to reduced operating expenses. In addition, Scinai is working on a debt-to-equity restructuring deal expected to positively impact shareholder equity by approximately $19 million. The company also announced a $2 million equity commitment from Daniel Stone, which will provide additional financial flexibility. Overall, the guidance highlights Scinai's focus on advancing its R&D pipeline and CDMO business while ensuring financial stability and growth.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.